Quan Joanne's Form 4 filing
Mirum Pharmaceuticals, Inc. (MIRM) · filed Jan 21, 2026
- Accession no.
- 0001670138-26-000001
- Filed
- Jan 21, 2026
- Trade date
- Jan 16-20, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $623.9K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Quan JoanneCIK 0001670138 | Officer (CHIEF MEDICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 16, 2026 | Common Stock | MOption exerciseAcquired | +12,500 | –F1 | – | 18,216 | Direct | |
| Jan 20, 2026 | Common Stock | SSaleDisposed | −6,911 | $90.27 | −$623,855.97 | 11,305 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 16, 2026 | Common Stock | MOption exerciseDisposed | −12,500 | $0.00 | $0 | 12,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Referenced by the price of 1 transaction in Table I.